SciSparc announced that the process of granting and validation for its core-technology patent has been completed in certain European countries. This patent covers combinations of cannabinoids and n-acylethanolamines. The Patent aligns seamlessly with the Company’s proprietary technology designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits. The Patent was granted and validated in Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Liechtenstein and the United Kingdom.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SPRC:
- SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
- SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
- SciSparc delivers treatment for ASD trial enabling commencement of dosing
- SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
- SciSparc files to sell 5.4M ordinary shares for holders